What does CK7 positive mean?

For example, a CK7-negative/CK20-positive phenotype is often associated with carcinomas of colorectal origin, whereas a CK7-positive/CK20-negative phenotype is seen in a wide variety of carcinomas, including carcinomas of the lung, breast, thyroid, pancreas, and female genital tract.

What is PAX8 positive?

PAX8-positive, calretinin-negative staining appears to be highly specific and sensitive for detecting metastatic ovarian serous carcinoma in cytological preparations and may prove useful for distinguishing these cells from mesothelial cells in fluid cytology (32).

What is gata3 positive?

In univariate analysis, the. presence of GATA-3 is a marker of good prognosis. and predicted for superior breast cancer–specific. survival, relapse-free survival, and overall survival.

How are carcinomas diagnosed using Immunohistochemical panels?

Effective systematic use of appropriate immunohistochemical panels enables accurate classification of most of the undifferentiated carcinomas as well as careful preservation of tissues for potential molecular or other ancillary tests. This review discusses the algorithmic approach to the diagnosis of CUPs using CK7 and CK20 staining patterns.

Is immunohistochemistry a useful screening tool for lung cancer screening?

The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J. Oncopathol. 2013;1:82. doi: 10.13032/tjop.2052-5931.100013.

What is the immunohistochemical profile of Merkel cell carcinoma (Kc7+)?

The immunohistochemical profile of a CK7−/CK20+ CUPs should include endocrine markers (Chromogranin, Synaptophysin and CD56) as this profile is unique to Merkel cell carcinomas and small cell carcinomas of the salivary glands, both with perinuclear “dot-like” CK20 staining.

What is the immunohistochemical profile of dMMR colorectal carcinoma?

The immunohistochemical profile of dMMR colorectal carcinomas can be variable: CK7−/CK20+ but also frequently CK7−/CK20− [46]. They are negative for CDX2 in 15% to 20% of cases [29]. SATB2 appears to be a more sensitive marker than CDX2 but its expression in the dMMR tumour group is not really known outside medullary carcinomas [36].